Parkinson’s disease study reveals how cancer drug reduces toxic protein in brain

This article was originally published here

The research team used a single low dose of Novartis’ leukemia drug Tasigna (nilotinib) in a phase II clinical trial in Parkinson’s disease patients. The researchers claimed that

The post Parkinson’s disease study reveals how cancer drug reduces toxic protein in brain appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply